Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Innovative Pharmaceutical Biotech ( (HK:0399) ).
Starcoin Group Limited has signed a memorandum of understanding with Chongqing-based Huamei Haibo Biotechnology to pursue strategic cooperation spanning equity investment, asset restructuring, Web3.0 healthcare, joint business development, financing, and a potential U.S. de-SPAC transaction. The collaboration framework also covers integration and commercialization of Huamei Haibo’s core cell-preparation systems, supplier and supply-chain platforms, exclusive cell-technology rights, equipment management, consumables distribution, and hospital-side data and financial technology systems.
By partnering with Huamei Haibo, a specialist in AI-driven cell manufacturing equipment and medical services with exclusive licenses for key cell standards and patents, Starcoin aims to secure exclusive access to proprietary cell technologies and technical services. The board expects this to strengthen the group’s R&D base, complement its oral insulin programme, and open pathways for commercialization and industrial deployment of advanced cell technologies, with the goal of building new revenue streams and reinforcing its positioning in biotech and healthcare.
The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.15 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
More about Innovative Pharmaceutical Biotech
Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, operates in the biotechnology and healthcare sector with a focus on pharmaceutical and related life-science technologies. The group is developing an oral insulin programme and is seeking to expand its presence across broader biotech and healthcare markets through strategic partnerships and advanced technology integration.
Average Trading Volume: 42,676,800
Technical Sentiment Signal: Sell
Current Market Cap: HK$340.7M
For a thorough assessment of 0399 stock, go to TipRanks’ Stock Analysis page.